Meet the 2018 ENDS US Speaker Lineup

  • Janet Aho

    VP, Regulatory Affairs and Product Safety MANE Inc.

    Janet has extensive experience with FDA regulations as a regulator, an auditor, and in private sector compliance.   She has spent more than 25 years in the flavor industry working with FDA, USDA and TTB regulations.  

    Janet currently serves on the Board of Governors of the US Flavor and Extract Manufacturers Association.   She also volunteers on an independent advisory board for The Department of Food Science and Technology at The Ohio State University.   

     These experiences have provided her with a unique perspective on the activities of federal regulatory agencies, the rulemaking process, and industry compliance issues. 

  • Vivien Azer

    Managing Director Cowen Outperform

    Vivien Azer is a managing director and senior research analyst specializing in the beverage, tobacco, and cannabis sectors. Ms. Azer is the first senior Wall Street analyst to cover the emerging cannabis sector, resulting in notable press coverage across periodicals such as The Economist, Barron’s and Forbes.

    Ms. Azer’s coverage of the tobacco sector earned her a spot on Institutional Investor’s All-America Research Team on several occasions. She has consistently been ranked by Thomson Reuters Analyst Awards (StarMine), and in 2017, she was ranked #1 and #2 for stock picking in beverages and tobacco, respectively, and #2 for earnings estimation in tobacco. Prior to joining Cowen and Company in 2014, she spent over nine years at Citi covering consumer staples. Ms. Azer holds a BA from the College of William and Mary and an MBA from NYU’s Stern School of Business.

  • Scott Ballin, JD

    Health Policy Consultant, Former VP, and Legislative Counsel Industry Advisor

    Scott D. Ballin has spent more than 40 years involved in issues related to tobacco and public health. He has worked on a spectrum of tobacco and nicotine issues ranging from labeling reforms on cigarettes and smokeless tobacco products to U.S. Food and Drug Administration (FDA) regulation of tobacco, excise taxes, clean indoor air laws and tobacco agriculture reforms.

    For more than 10 years he served as the American Heart Association’s vice president and legislative counsel, as well as a steering committee member and two-time chairman of the Coalition on Smoking or Health, which was the first truly active national coalition in the tobacco control movement.

    He served on the steering committee of the Alliance for Health Economic and Agriculture Development (AHEAD), an organization formed to bring parties together to work for the enactment of recommendations contained in a presidential report, “Tobacco at a Crossroads.”

    In recent years he has worked as an advisor to the University of Virginia on a series of dialogues—“The Morven Dialogues”—on tobacco, nicotine and harm reduction, and he also served as a consultant and advisor to the Food and Drug Law Institute’s tobacco conferences in 2016 and 2017.

    He has authored a series of white papers on tobacco harm reduction, and he has given expert testimony before the U.S. Congress and the FDA on numerous occasions. Ballin is a graduate of the Georgetown University School of Foreign Service and a graduate of the George Mason University Antonin Scalia School of Law in Arlington, Virginia, USA.

  • Paul Blair

    Director of Strategic of Initiatives Americans for Tax Reform (ATR)

    As the Director of Strategic of Initiatives at Americans for Tax Reform (ATR), Paul Blair handles and oversees a broad portfolio of state, local, and federal policy issues and projects, including free market energy reform, tobacco harm reduction, criminal justice reform, and pro-taxpayer state preemption efforts.

    As part of this portfolio, Blair works with state and federal lawmakers, third party groups and associations, and political committees and PACs to achieve ATR’s tax and regulatory agenda. He also manages ATR’s outreach to a number of federal departments and agencies.

  • Azim Chowdhury

    Partner Keller and Heckman LLP

    Azim Chowdhury practices food, tobacco and e-vapor law in the Washington, D.C. office of Keller and Heckman LLP. Mr. Chowdhury advises domestic and foreign corporations in matters of Food and Drug Administration (FDA) and international regulatory compliance. In particular, he assists corporations in establishing clearances for food and drug additives in the U.S., Canada, and European Union, with an emphasis on indirect additives used in food-contact materials. Mr. Chowdhury has also developed expertise in tobacco product regulation and spearheaded the Tobacco and E-Vapor practice at Keller and Heckman. Specifically, Mr. Chowdhury has experience representing tobacco and electronic vapor product (e-cigarette) manufacturers, suppliers, and trade associations in matters of FDA regulatory and corporate compliance. He is also a frequent contributor to the Tobacco Reporter and the Food and Drug Law Institute’s Update magazine; edited and co-authored FDLI’s tobacco regulation manuals, Tobacco Regulation and Compliance: An Essential Resource and Tobacco and Nicotine Delivery: Regulation and Compliance, 2nd Edition; and previously served on the Editorial Advisory Board of the Food and Drug Law Journal.  Prior to entering private practice, he served as a judicial law clerk on the Court of Special Appeals of Maryland.  Mr. Chowdhury received a B.A. and B.S. from Johns Hopkins University, a MBA from the University of Maryland Robert H. Smith School of Business, and a JD, cum laude, from the University of Maryland School of Law.

  • Alex Clark

    Executive Director The Consumer Advocates for Smoke-free Alternatives Association (CASAA)

    Alex Clark is the CEO of The Consumer Advocates for Smoke-free Alternatives Association (CASAA). He comes from a background in customer service and logistics. Shortly after discovering the value of Tobacco Harm Reduction, he began volunteering his time for CASAA and was appointed to serve on CASAA’s Board of Directors in 2014, and later that same year was elected as CASAA’s Legislative Director. Mr. Clark stepped down from the Board of Directors in January 2016 in order to accept a position as CASAA’s Legislative Coordinator and was promoted by the Board to CEO in March 2017. Mr. Clark is responsible for overseeing all of CASAA’s advocacy efforts.

  • Gregory Conley

    President American Vaping Association

    Gregory Conley is the president of the American Vaping Association (AVA), a nonprofit organization that champions regulatory policies toward vapor products designed to maximize the effectiveness of vaping for quitting smoking. He is one of the most prominent defenders of vaping in the United States, and has appeared on CNN, Fox News, and MSNBC. In addition to his work with the AVA, Mr. Conley is an attorney, a consultant on vaping legislative and regulatory issues, and an advisor on grassroots issues to the Smoke-Free Alternatives Trade Association. He began working on vaping issues in 2010 after quitting smoking with a vapor product while in law school. 

  • Doug Copeland

    Executive Vice President High Point Clinical Trials Center

    Doug Copeland serves as Executive Vice President of the High Point Clinical Trials Center.

    His professional career spans a number of roles in North Carolina and in Washington, DC.  Prior to his role at High Point Clinical Trials Center, he spent 16 years as President of a regional media company, the Triad Business Journal.  He served as Vice President of Cone Health from 1981 – 1999.  During that time he was a part of a turnaround team that restructured the hospital and grew it from a single building to a multi-hospital system.  He also served 10 years as an IRB board member reviewing clinical trials.  He served in Washington as Chief of Staff to U. S. Congressman Richardson Preyer of North Carolina.  He also served in the White House doing advance work and issues management for President Jimmy Carter and served Carter on his national campaign staff in 1976.

    Doug is a graduate of the University of North Carolina - Chapel Hill.  He received the National Leadership Award from the National Association of Community Leadership Programs and the Spirit of Entrepreneurship Award from Junior Achievement of Central North Carolina.  In 2017 he was awarded the Greensboro Chamber of Commerce’s Maleska Award for a lifetime of public service.

    He serves in a number of leadership roles including; the Novant - Forsyth Hospital Foundation Board, the Board of Visitors of High Point University, chair of the Governmental Affairs Committee of the Greensboro Partnership, the Board of Visitors of the University of North Carolina Greensboro.   He also serves on the boards of the Old North State Council of the Boy Scouts of America, and is immediate past president of Greensboro Rotary.

  • Dr. Ian M. Fearon

    Senior Director Clinical and Regulatory Affairs EMEA JUUL Labs

    Ian is a Senior Director Clinical and Regulatory Affairs EMEA at JUUL Labs. He specializes in the biological and psychological effects of nicotine, clinical studies to assess the biological effects of electronic cigarettes and tobacco heating devices, and the scientific basis for regulation.  Prior to joining JUUL, Ian was Principal Scientist and Head of Clinical Research at British American Tobacco's central research and development center in Southampton, U.K. Prior to joining BAT in 2008, he pursued an academic career as a Lecturer in Physiology at the University of Manchester and an Assistant Professor at McMaster University in Hamilton, Canada.  Ian is a highly-cited scientific researcher and writer, contributing to more than 50 peer-reviewed papers and book chapters and generating over 1,900 citations.

  • David Graham

    Chief Impact Officer NJOY

    David Graham is Chief Impact Officer at NJOY, a role which leads efforts across the company to maximize the positive impact on public health of the company’s products and services through increasing their reach and effectiveness while including oversight of regulatory affairs for the company. He has extensive experience in nicotine and non-nicotine new product development, tobacco control policy, and related regulation in the international healthcare and e-vapor industries spanning ~ 25 years. Beginning with nicotine replacement therapy (NRT)/smoking cessation products in the UK in 1992, followed by International product and category development roles in Sweden, he moved to the USA in 2000 with Pharmacia, subsequently becoming part of Pfizer and then moving to Johnson & Johnson.

    In 2013, he joined NJOY to lead the regulatory affairs, quality & compliance function for the company and prepare for regulation by FDA and other regulatory agencies in the US and abroad. In addition to multiple interactions with FDA, and other regulatory agencies internationally, David co-led NJOY’s engagement with the National Institute of Drug Abuse (NIDA) on its Small Business Innovation Research (SBIR) award for NJOY to develop an Electronic Nicotine Delivery System (ENDS) for use for clinical research in smoking cessation, leading to the establishment of the first FDA Drug Master File (DMF) for ENDS products. In late 2016, David co-founded and was President of Reveritas Group, a multi-partner consultancy firm of specialists and preferred providers formed to aid ENDS companies navigate all aspects of FDA’s Premarket Tobacco Application (PMTA) process via a total programming approach, and/or provide select outsourced resources as required. Following FDA’s extension of the PMTA compliance deadline, David returned to NJOY in August 2017 in his current role.

    David is a graduate of Columbia University with a Master’s in Public Policy & Administration.

  • Bonnie Herzog

    Managing Director and Senior Tobacco, Beverage and Convenience Store Analyst Wells Fargo Securities

    Bonnie Herzog is a Managing Director and Senior Tobacco, Beverage and Convenience Store Analyst at Wells Fargo Securities. During her 15-plus years of experience as a sell-side equity research analyst, Bonnie has been a top-ranked Institutional Investor analyst. For 10 years, Institutional Investor magazine selected Bonnie for the “All-America Research Team,” primarily ranking her as No. 2 in the tobacco sector.

  • Eric Heyer

    Partner Thompson Hine LLP

    Eric Heyer is a partner in Thompson Hine LLP's Washington, D.C. office and leads the firm's vaping practice.  Eric was integrally involved in the first federal lawsuit in 2009 that successfully challenged FDA's categorization of ENDS products as unapproved new drugs or medical devices and helped open the doors to the expansion of the industry in the United States.  Over the years, Eric has counseled and represented both foreign and domestic ENDS and e-liquid manufacturers, wholesalers, distributors, and retailers on all manner of federal and state regulatory compliance issues.  Eric has also represented clients in Proposition 65 litigation and in a successful constitutional case challenging Indiana's statutory scheme regulating the manufacture of e-liquids.  

  • Chris Howard

    VP, General Counsel and Chief Compliance Officer E-Alternative Solutions, LLC

    Chris Howard is Vice President, General Counsel and Chief Compliance Officer for E-Alternative Solutions, LLC, a marketer and distributor of vapor products and sister company to Swisher International, based in Jacksonville, Florida.  Mr. Howard is responsible for overseeing EAS’s legal activities and policies, as well as compliance, regulatory affairs and brand protection.  Mr. Howard provides industry leadership among vapor manufacturers and distributors in light of both a rapidly evolving regulatory landscape of the vaping industry and the developing science globally with respect to the vapor category.  Mr. Howard also currently serves on the Vapor Technology Association Board of Directors. 

    Previously, Mr. Howard was General Counsel and Chief Compliance Officer for Fontem Ventures, the manufacturer of blu eCigs products, and he has also held senior legal positions with Lorillard Tobacco Company and ITG Brands, LLC.  During his tenure in these positions, Mr. Howard had primary responsibility for managing complex legal and regulatory issues related to both the tobacco and vaping industries.  He has also served as lead counsel for a division of a global agricultural chemical company and worked on a trial team for a law firm defending product liability litigation against a tobacco product manufacturer.

    Mr. Howard is a frequent speaker on marketing issues and other trends related to the vapor industry.  He has a B.B.A. in Business Management and Marketing from James Madison University and a J.D. from The T.C. Williams School of Law at University of Richmond. 

  • Pamela Kaufman

    Vice President Morgan Stanley Research

    Pamela Kaufman is a Vice President covering the Tobacco and Packaged Food industries. Pamela joined Morgan Stanley’s research department in 2013. Prior to joining Morgan Stanley, Pamela worked in equity research at UBS covering the Hardlines sector, and prior to that, was a financial analyst at Wolf Popper, a securities class action litigation firm. Pamela also worked as an investment analyst at Enso Capital, a long/short equity hedge fund. Pamela received her BS in Finance and MBA from the NYU Stern School of Business, and holds the Charted Financial Analyst (CFA) designation.

  • Jeffrey Kim, D.D.S., Ph.D.

    Project Leader American Dental Association Volpe Research Center

    Jeffrey Kim D.D.S., Ph.D., is a clinician-scientist with 10 years of research experience at Federal Government research institutions, universities and non-profit research center. Continuous NIH grant funding since 2005. He is a recognized expert in oral cancer epigenetics, stem cell biology, nicotine toxicology and e-cigarette testing standards. Member to U.S. TAG for ISO/TC 106. Published author and editorial reviewer in leading journals, and invited speaker to ADA CERP, FDA, NIH, NIST, and DoD.

  • Patricia I. Kovacevic

    General Counselor and Chief Compliance Officer Consultant Independent Consultant

    A global legal and compliance industry expert Patricia I. Kovacevic’s experience comprises general counsel and chief compliance officer roles at Nicopure Labs LLC, and leading senior legal and compliance positions at, among others, Philip Morris International and Lorillard. Prior to joining Lorillard she was a partner at Patton Boggs. Her expertise includes global e-cigarette and tobacco regulation, compliance and all regulatory aspects of marketing/media communications, corporate affairs, criminal investigations, FCPA, trade sanctions, privacy, product development and launch. Kovacevic served on the board of directors of the Vapor Technology Association and on the advisory board of the Global Tobacco & Nicotine Forum. In the past she was a United Nations staff member, served on the U.N.’s Public-Private Partnership Commission and was also an adviser to the Council for Burley Tobacco. Kovacevic is admitted to practice in New York and before the Supreme Court of the United States. She holds a J.D. from Columbia Law School in New York and has completed the Harvard Business School “Corporate Leader” course. She is fluent in seven European languages. 

  • Amy Madl

    Senior Principal Health Scientist Cardno ChemRisk

    Dr. Amy Madl is a Senior Principal Health Scientist with Cardno ChemRisk.  She has a M.S. and Ph.D. in Pharmacology and Toxicology, is a Diplomate of the American Board of Toxicology (DABT), and has focused her academic and consulting experience in the field of inhalation toxicology.  She has nearly 20 years of experience in the sampling and analysis, toxicology, exposure, and risk assessment of airborne chemicals.  Dr. Madl also holds an adjunct position as a Research Associate with the University of California, Davis, where she has served as a co-investigator on multidisciplinary research teams for inhalation research studies.  Her expertise also includes methods for characterization of electronic nicotine delivery systems, including aerosol chemistry and toxicology, consumer exposures, toxicology and pharmacokinetic studies, and human health risk assessments.  Dr. Madl has published over 75 abstracts, book chapters, and peer-reviewed papers on various exposure, toxicology, and risk-related topics.

  • Dr. Daniel Norwood

    Executive Partner SCIO Analytical & Senior Consultant at Smithers Rapra

    Dr. Daniel Norwood joined SCIO Analytical as Executive Partner in June 2015. Prior to SCIO Analytical, Dr. Norwood was a key technical employee at Boehringer Ingelheim Pharmaceuticals where he was successful in various pharmaceutical development roles, including Director Physical and Chemical Analysis.  In June 2015, Dr. Norwood retired with the title of Distinguished Research Fellow in Analytical Development.  Prior to joining Boehringer Ingelheim, Dr. Norwood, with Dr. Feinberg, founded the Structural Chemistry Group at Magellan Laboratories, later Catalent Pharma Solutions, which became widely recognized for its work in pharmaceutical impurity structure elucidation, and in leachables and extractables characterization. Prior to Magellan, he was a pharmaceutical development scientist at the Glaxo Research Institute.  

    Dr. Norwood is an internationally recognized expert in the field of leachables and extractables assessment in pharmaceutical development and manufacturing.  He served as chair of the widely-quoted Product Quality Research Institute (PQRI) Working Group on leachables and extractables in inhalation drug products. He is also a member of the PQRI Working Group on leachables and extractables in parenteral and ophthalmic drug products (PODP), and has served on various technical teams of the International Pharmaceutical Aerosol Consortium on Regulations and Science (IPAC-RS). Since 2010, he has served as a member of the USP Expert Committee on Packaging, Storage and Distribution where he chairs the subcommittee on extractables and leachables. Dr. Norwood has received several industry awards, including the CEO’s Award from Glaxo (1994), the President’s Award from Boehringer Ingelheim (2007), the Excellence in Research Award from PQRI (2009), and the Award for an Innovative Response to Public Health Challenges from USP (2013). Dr. Norwood completed his bachelor’s degree in Biochemistry at Virginia Tech and his doctorate degree in Environmental Chemistry at the University of North Carolina at Chapel Hill, School of Public Health.

  • Tim Phillips

    Managing Director ECigIntelligence

    The founder and managing director of ECigIntelligence, Tim is a UK-qualified attorney, having worked at the European Commission, BSkyB and Herbert Smith (an international law firm), AOL Europe, as director of public affairs at Betfair (IPO in 2010 valued at £1.5bn), and as a partner in a New York VC-funded start-up in the diamond sector. Tim holds a Postgraduate Diploma in Legal Practice from the University of Law, London and a Masters in Geology from Oxford University.

  • Ryan Potts, PhD, DABT

    Vice President, Scientific & Regulatory Affairs RAI Services Company

    Ryan Potts, PhD, DABT, serves as Vice President of Product Integrity in the Scientific & Regulatory Affairs group for RAI Services Company in Winston-Salem, North Carolina. RAIS is a wholly owned subsidiary of Reynolds American Inc., part of the BAT Group of companies. As Vice President of Product Integrity, he leads a team that encompasses product stewardship, clinical studies, non-clinical studies, biomarker research and certain regulatory compliance functions. He holds MSc and PhD degrees in toxicology and is board certified by the American Board of Toxicology.

  • Christopher Russell

    Senior Research Fellow, Behavioural Studies of Tobacco and Nicotine Use Centre for Substance Use Research (CSUR)

    Christopher Russell (Ph.D.) is a behavioural psychologist and senior research fellow at the Centre for Substance Use Research (CSUR), Glasgow, Scotland. Dr Russell leads the Centre’s behavioural studies of tobacco and nicotine use in the United Kingdom and United States.

    Dr Russell conducts pre-market and post-market behavioural studies that aim to characterise the likely impact of marketing specific vapor products on tobacco use behaviour among current, former and never smokers. Through cross-sectional and longitudinal surveys, Dr Russell models the prevalence of different chronologies of initiation, cessation and re-initiation of cigarette smoking and e-cigarette use within large cohorts of adult vapers, and identifies patterns of e-cigarette use that are associated with successful and unsuccessful attempts to switch from smoking to vaping. Most recently, Dr Russell’s 2016 U.S. Vapers Survey obtained data on the vaping devices, flavors and nicotine strengths being used by 15,807 adult frequent vapers in the United States to switch completely from smoking to vaping. Dr Russell is also leading studies of U.S. nationally representative samples of current, former and never smokers who are also never-vapers to assess the role of perceptions of product attractiveness, health risk, and addiction risk as predictors of intentions to begin using specific vapor products.

    The results of this work are used to identify the people, products, patterns of use, and regulatory policies that are most likely to encourage and assist smokers to switch to vaping, and to advise against the adoption of regulations and legislation that may reduce the accessibility, affordability, appeal and effectiveness of e-cigarettes as a way of quitting smoking.

  • Erica Spies, PhD

    Senior Scientist Philip Morris R&D Biomedical

    Erica Spies, PhD, obtained a MS in Community and Behavioral Health in 2009 and a PhD in Community and Behavioral Health with a subtrack in Health Communication in 2013 from the College of Public Health at the University of Iowa, Iowa City, Iowa, USA. As a mixed-methods trained behavioral scientist, she has experience in applied public health research, public health surveillance, the application of behavior change theories to public health problems, and the design, implementation, and evaluation of public health interventions and health communication campaigns. At PMI, Erica provides technical leadership in Behavioral Sciences to support new product frameworks, strategies, and plans, and develop and manage the implementation of Behavioral Research methods and measurements in close cooperation with Clinical, Perception and Behavior Assessments, and post-marketing assessment for new products.

  • Dr Andrea Vansickel

    Manager Consumer & Marketplace Insights Altria Client Services

    Andrea Rae Vansickel, Ph.D. is a classically trained behavioral pharmacologist, educated in experimental psychology-behavioral neuroscience, and psychopharmacology at the University of Kentucky and in the clinical pharmacology of tobacco at Virginia Commonwealth University.   Dr. Vansickel has published over 20 papers and book chapters related to human models of drug self-administration, human drug discrimination, human abuse liability testing, and the clinical pharmacology of e-vapor products, among others.  Dr. Vansickel has been building programs and infrastructure to support regulatory research and engagement efforts for Altria since January of 2012. These programs relate to tobacco abuse liability testing, e-vapor topography, cross-sectional surveys, actual use trials and, most recently, prospective cohort studies. 

  • Crystal Wersching

    Sr. Director of the Procurement Center of Excellence Altria

    Crystal Wersching is the Sr. Director of the Procurement Center of Excellence at Altria, a Fortune 200 company headquartered in Richmond, Virginia.  Altria has built some of the best known brands in the world – Marlboro, Copenhangen, Skoal, and Black & Mild. 

    Crystal’s team develops procurement strategies that optimize the value of goods and services at Altria through 4 key areas of focus: 

     

    1. Sourcing – how we identify and collaborate with suppliers

    2. Supplier management – how we select and monitor supplier performance

    3. Corporate responsibility – how we mitigate risk in our supply chain to deliver economic, social and environmental benefits to our stakeholders

    4. ​Talent – how we continuously develop our supply chain talent

     

    Crystal joined Altria in 2003 where she spent a majority of her career in the Finance organization.  She performed various roles in Accounting, Finance Decision Support, Strategy & Business Development, and Corporate Planning prior to assuming her role in Procurement.  Her education includes a B.A. in Accounting from Randolph-Macon College, Master’s in Accounting and Financial Management, and Master’s in Business Administration.  Prior to joining Altria, she worked in the banking industry in various roles including internal audit, cash management, and mortgage lending.  She lives near Richmond, Virginia with her husband and 11 year-old son.

  • David Wourms

    Senior Research Scientist Battelle Memorial Institute

    Mr. Wourms has an educational background in the Applied Behavioral Sciences that includes extensive graduate-level work in human factors/experimental psychology, and certification in performing Optimizing Human Performance Front-end Analyses. He has more than 20 years of experience leading applied human sciences related projects for medical and commercial companies. He provides Human Factors leadership for medical device development specifically focused on meeting the unique, risk management centered requirements of the Federal Drug Administration (FDA).